Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly over time, despite perpetually increasing knowledge of human ...

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is aiming to position itself at the intersection of ...

Oxford-based pharmaceutical firm Exscientia has agreed to an acquisition by Recursion, a biotech from Utah, US, in a transaction worth $688 million. The deal comes as major firms look to AI – as ...

Operational complementarities expected to yield annual synergies of approximately $100 million ...